Literature DB >> 33907091

Establishment and assessment of a nomogram model for predicting the risk of fulminant myocarditis: A STROBE compliant cross-sectional study.

Guifen Xu1,2, Feizhen Chen3, Wenxiang Zhao1, Yong Zheng1, Wei Zhuang1, Fuling Yu1.   

Abstract

ABSTRACT: We aimed to identify potential clinical predictors associated with the risk of fulminant myocarditis, and further to establish and assess a nomogram model based on significant attributes for clinical practicability.This is a retrospective, cross-sectional study, involving 28 patients with fulminant myocarditis and 35 age-, and sex-matched patients with non-fulminant myocarditis. Effect-size estimates are expressed as odds ratio (OR) and 95% confidence interval (CI).Fifteen factors were primarily identified to be associated with the significant risk of fulminant myocarditis after adjusting for confounders. Due to strong correlation, 6 factors were retained, including mean arterial pressure (OR, 95% CI, P: .82, .72-.94, .005), creatinine (2.15, 1.13-4.10, 0.020), blood urea nitrogen (1.45, 1.04-2.02, 0.028), aspartate aminotransferase (2.62, 1.16-5.91, 0.021), troponin I (1.43, 1.07-1.90, 0.015), and ventricular wall motion abnormality (25.81, 2.52-264.69, 0.006). The contribution of the 6 significant factors to predicting fulminant myocarditis risk was significant from multi-angle analyses, and regressing these factors in a nomogram model exhibited good predictive accuracy, as reflected by both C-index (>90%, P < .001).We have identified 6 clinical factors in significant association with fulminant myocarditis, and their prediction capability was more obvious in a nomogram model. Further investigations with larger sample sizes and longer follow-up intervals are warranted.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33907091      PMCID: PMC8084052          DOI: 10.1097/MD.0000000000025317

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Fulminant myocarditis is a relatively rare syndrome clinically characterized by sudden and severe diffuse cardiac inflammation, and it frequently leads to fatal outcomes, such as ventricular arrhythmias, cardiogenic shock, and multiple organ failure.[ These fatal outcomes often occur in the acute stage, and if treated promptly, the survival rate for patients with fulminant myocarditis can reach over 50%.[ Hence, the early identification of individuals at high risk for fulminant myocarditis is crucial to implement measures that may prevent the progression to overt fulminant myocarditis and reduce the occurrence of resultant fatal outcomes.[ In medical literature, some clinical manifestations or laboratory biomarkers have been identified as promising predictors for the development of fulminant myocarditis.[ For example, low systolic blood pressure and high creatine kinase were reported to be associated with an increased risk of fulminant myocarditis.[ Besides, echocardiography, as a noninvasive and easily performed technique to examine heart structures and function, is widely used in assessing fulminant myocarditis.[ Current evidences have showed that fulminant myocarditis is distinguishable from non-fulminant myocarditis by echocardiography,[ and echocardiography can further provide prognostic insights.[ Thus, early appraisal based on the integration of clinical, biological, and echocardiographic characteristics is important and imperative. To yield more information for further investigations, we undertook a retrospective, cross-sectional study based on 28 patients with fulminant myocarditis and 35 age-, and sex-matched patients with non-fulminant myocarditis to identify potential predictors associated with the risk of fulminant myocarditis. Meanwhile, to enhance clinical practicability, we next attempted to establish and assess a nomogram prediction model for fulminant myocarditis based on significant attributes.

Methods

Ethical approval and informed consent

The conduct of this present study was reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Fujian Medical University. Written informed consent was obtained from all study subjects if they had the capacity to provide it, and if subjects cannot give consent, a relative or representative gave proxy consent.

Study design and subjects

This is a retrospective, cross-sectional study conducted during the period from January 2016 to December 2018 at the Department of Cardiology, The First Affiliated Hospital of Fujian Medical University. A total of 63 adult subjects were enrolled in this study, involving 28 patients with fulminant myocarditis and 35 age-, and sex-matched patients with non-fulminant myocarditis.

Definitions of fulminant myocarditis

Fulminant myocarditis is defined as the sudden and severe diffuse cardiac inflammation, accompanied by hemodynamic dysfunction (such as ventricular arrhythmias, cardiogenic shock), or multiple organ failure.[

Baseline characteristics

At the time of admission, data on demographic and lifestyle factors, clinical characteristics, laboratory biomarkers, and echocardiographic indexes were recorded and double checked for the sake of accuracy. Demographic factors included age at the time of admission and sex. Lifestyle factors included cigarette smoking and alcohol drinking status. Smoking was classified into never smoking and ever (current or former) smoking. Drinking was classified into never drinking and ever (current or former) drinking. Clinical characteristics included mean arterial pressure (MAP) and pulse. Laboratory biomarkers (units) included white blood cells (×109/L), neutrophil percentage (%), neutrophil count (×109/L), lymphocyte count (×109/L), hemoglobin (g/L), platelet (×109/L), C-reactive protein (mg/L), procalcitonin (ng/L), blood glucose (mmol/L), Kalium (mmol/L), magnesium (mmol/L), uric acid (μmol/L), creatinine (μmol/L), blood urea nitrogen (BUN) (mmol/L), D-dimer (mg/L), fibrinogen (g/L), NT-proBNP (brain natriuretic peptide) (pg/mL), troponin I (TNI) (ng/mL), lactate dehydrogenase (U/L), creatine kinase (U/L), MB isoenzyme of creatine kinase (U/L), total bilirubin (μmol/L), direct bilirubin (μmol/L), albumin (g/L), alanine aminotransferase (U/L), aspartate aminotransferase (U/L), total cholesterol (mmol/L), triglyceride (mmol/L), high-density lipoprotein (HDL) (mmol/L), and low-density lipoprotein (LDL) (mmol/L). At the time of admission, echocardiographic indexes were measured, including left atrium dimension (LAD), left ventricular end diastolic diameter (LVEDD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (IVPWT), stroke volume (SV), left ventricular ejection fraction (LVEF), and ventricular wall motion abnormality (VWMA). In addition, the same echocardiography was done after 3 months after discharge from The First Affiliated Hospital of Fujian Medical University, and these indexes were recorded and compared with the initial records.

Statistical analyses

Statistical analyses were performed using the STATA software (version 14.0, Stata Corp., TX) and R programming environment (version 4.0.2). Two-sided P values <.05 were considered statistically significant. Continuous variables were assessed for normality by use of the skewness and kurtosis test, and they are presented as median (interquartile range) for skewed variables. Categorical variables are presented as count (percentage). Rank-sum test or Chi-squared test was used to compare baseline characteristics between groups. Logistic regression analyses were done to identify statistically significant factors attributable to fulminant myocarditis before and after adjusting for confounders, including age, sex, cigarette smoking, and alcohol drinking. Effect-size estimates are expressed as odds ratio (OR) and 95% confidence interval (CI). Spearman correlation analyses were used to illustrate the relationship of significant factors, and those with pairwise correlation coefficient <0.5 were selected as potential independent predictors for fulminant myocarditis. Predictive accuracy was appraised by adding significant characteristics to the basic model, which included age, sex, cigarette smoking, alcohol drinking, and C-reactive protein (CRP). Akaike information criterion (AIC), Bayesian information criterion (BIC), the -2-log likelihood ratio test, and Hosmer–Lemeshow goodness-of-fit test were used to evaluate how closely the prediction probability by adding significant characteristics was. Integrated discrimination improvement (IDI) and area under the receiver operating characteristic (AUROC) were used to see whether the addition of significant factors can differentiate patients with fulminant myocarditis from non-fulminant myocarditis. The receiver operating characteristic (ROC) curves were plotted for models with and without significant factors. Finally, a prediction nomogram model for fulminant myocarditis was established by implementing “rms” package in the R programming environment. The area under the receiver operating characteristics curve (concordance index or C-index) was used to justify the predictive accuracy.

Results

The baseline characteristics of study subjects are summarized in Table 1. Five deaths in patients with fulminant myocarditis occurred. Compared with patients with non-fulminant myocarditis, patients with fulminant myocarditis tended to have lower MAP, worse biological, and echocardiographic performance.
Table 1

The baseline characteristics of study subjects.

Patients with FMPatients with NFM
Characteristics(n = 28)(n = 35)P
Age, y47.5 (37, 63)48 (38, 69).63
Males14 (50%)17 (49%).74
Cigarette smoking9 (32.1%)11 (31.4%).93
Alcohol drinking6 (21.4%)10 (28.6%).67
MAP, mm Hg96.33 (82.67, 107)134 (122.67, 148)<.01
Pulse (per minute)82 (60, 96)80 (70, 90).78
Laboratory biomarkers
WBC (×109/L)8.19 (7.37, 9.14)6.43 (5.27, 8.01).01
Neutrophil percentage (%)82.35 (73.2, 85.8)66.6 (52.9, 73.1)<.01
Neutrophil count (×109/L)6.06 (5.43, 7.38)4.29 (3.05, 5.72)<.01
Lymphocyte count (×109/L)0.96 (0.82, 1.45)1.45 (1.05, 1.77).04
Hemoglobin, g/L141.5 (127, 145)141 (131, 151).89
Platelet (×109/L)213.5 (133, 222)214 (182, 231).26
CRP, mg/L26.99 (11.23, 51.46)20.62 (5.46, 49.95).55
Procalcitonin, ng/L0.19 (0.08, 0.8)0.07 (0.05, 0.18).04
Blood glucose, mmol/L10.63 (7.02, 13.71)5.33 (4.48, 6.56)<.01
Kalium, mmol/L3.96 (3.76, 4.19)4.2 (3.87, 4.36).15
Magnesium, mmol/L0.95 (0.88, 1.02)0.87 (0.82, 0.93).07
Uric acid, μmol/L375.95 (261, 461)326.8 (249, 364.6).18
Creatinine, μmol/L74 (56.6, 98.7)64 (61, 70.5).25
BUN, mmol/L8.43 (4.92, 10.08)4.5 (3.9, 6.42)<.01
D-dimer, mg/L2.12 (0.8, 3.57)0.33 (0.21, 0.51)<.01
Fibrinogen, g/L3.56 (2.57, 4.15)3 (2.36, 3.84).36
NT-proBNP, pg/mL8965 (5700, 21500)291 (82, 675.8)<.01
TNI, ng/mL4.35 (0.67, 8)0.77 (0.28, 1.6).01
LDH, U/L556.5 (414, 863)245 (207, 288)<.01
Creatine kinase, U/L443.5 (114, 943)209 (83, 350).06
CKMB, U/L59.5 (19, 77)21 (12, 31).02
Total bilirubin, μmol/L12.3 (8, 18.7)10.3 (6.9, 13.8).21
Direct bilirubin, μmol/L5.55 (3.4, 7)3.9 (2.9, 5.6).06
Albumin, g/L38.5 (35.5, 40.6)38.2 (36.6, 41.7).48
ALT, U/L101 (51, 140)23 (16, 43)<.01
AST, U/L138.5 (38, 254)34 (23, 48)<.01
Total cholesterol, mmol/L3.6 (3.32, 4.68)3.61 (3.16, 4.24).84
Triglyceride, mmol/L0.89 (0.68, 1.33)1.06 (0.53, 1.39).81
HDL, mmol/L0.95 (0.7, 1.27)1.05 (0.83, 1.22).47
LDL, mmol/L2.52 (1.75, 3.13)2.1 (1.96, 2.63).30
Echocardiographic indexes
 LAD, cm3.52 (3.3, 3.98)3.58 (3.24, 3.90).99
 LVEDD, cm4.9 (4.32, 5.17)4.87 (4.61, 5.01).84
 IVST, cm1.13 (1.02, 1.29)0.89 (0.82, 0.94)<.01
 IVPWT, cm0.98 (0.91, 1.13)0.79 (0.72, 0.84)<.01
 SV, mL51.63 (45.66, 63.36)72.09 (66.81, 79.73)<.01
 LVEF (%)50.13 (38.1, 58.43)67.16 (62.7, 70.06)<.01
 VWMA16 (57.1%)2 (5.7%)<.01
The baseline characteristics of study subjects.

Identification of statistically significant characteristics

Table 2 displays the identification of statistically significant factors for fulminant myocarditis. Fifteen factors, including MAP, blood glucose, D-dimer, creatinine, BUN, aspartate aminotransferase (AST), TNI, lactate dehydrogenase (LDH), creatine kinase (CK), MB isoenzyme of creatine kinase (CKMB), IVST, IVPWT, SV, LVEF, and VWMA, were observed to be significantly associated with the risk of fulminant myocarditis after adjusting for age, sex, cigarette smoking, and alcohol drinking (all P < .05). Three factors were predictive for fulminant myocarditis, including MAP (OR, 95% CI, P: .84, .72–.94, .005), SV (0.85, 0.76–0.95, 0.003), and LVEF (0.81, 0.70–0.93, 0.003). By contrast, the other factors were risky for fulminant myocarditis, including D-dimer (5.90, 1.65–21.34, 0.006), creatinine (2.15, 1.13–4.10, 0.020), BUN (1.45, 1.04–2.02, 0.028), TNI (1.43, 1.07–1.90, 0.015), and IVPWT (5.53, 1.82–16.86, 0.003).
Table 2

Identification of significant factors for the risk of fulminant myocarditis before and after adjustment.

Unadjusted modelAdjusted model
Significant factorsOR95% CIPOR95% CIP
MAP0.82(0.72–0.94).0040.82(0.72–0.94).005
Blood glucose1.76(1.25–2.48).0011.99(1.24–3.20).005
D-dimer4.89(1.64–14.58).0045.90(1.65–21.34).006
Creatinine (per 10 increment)1.46(0.99–2.16).0532.15(1.13–4.10).020
BUN1.55(1.13–2.12).0061.45(1.04–2.02).028
AST (per 50 increment)2.32(1.23–4.69).0102.62(1.16–5.91).021
Troponin I1.43(1.09–1.88).0101.43(1.07–1.90).015
LDH (per 100 increment)2.91(1.50–5.62).0023.44(1.48–7.96).004
Creatine kinase (per 20 increment)2.14(1.05–4.65).0354.64(1.28–16.84).020
CKMB (per 10 increment)1.63(1.15–2.31).0061.85(1.14–3.00).013
IVST (per 0.1 increment)5.22(1.92–14.15).00114.32(2.33–88.18).004
IVPWT (per 0.1 increment)6.08(1.94–19.03).0025.53(1.82–16.86).003
SV0.87(0.81–0.95).0010.85(0.76–0.95).003
LVEF0.81(0.71–0.92).0010.81(0.70–0.93).003
VWMA30.00(3.31–272.34).00325.81(2.52–264.69).006
Identification of significant factors for the risk of fulminant myocarditis before and after adjustment.

Correlation analyses

Spearman correlation analyses revealed that there were close correlations of blood glucose, D-dimer, LDH, CK, CKMB, IVST, SV, LVEF, and IVPWT with the other significant factors (pairwise correlation coefficients >0.8) (Supplementary Figure 1). Finally, MAP, creatinine, BUN, AST, TNI, and VWMA were selected as potential predictors for fulminant myocarditis.

Prediction accuracy assessment

Two models were constructed to assess the prediction accuracy of identified predictors, viz., the basic model and the full model. The basic model included age, sex, cigarette smoking, alcohol drinking, and pulse, and the full model additionally included MAP, creatinine, BUN, AST, TNI, and VWMA. As presented in Table 3, both calibration and discrimination statistics were assessed by adding identified predictors to the basic model. Compared with the basic model, prediction accuracy was significantly improved in the full model (all P < .05). The benefits gained by adding significant predictors to the basic model were higher than that of the basic model (Fig. 1).
Table 3

Prediction accuracy gained by adding significant factors identified to basic model in predicting fulminant myocarditis risk.

StatisticsBasic modelFull model
AIC38.3555.96
BIC50.0577.85
HL test (P value)0.8810.953
LR test (P value)0.011
NRI (P value)0.008
IDI (P value)<0.001
AUROC (P value)0.019
Figure 1

Decision curve analysis on the net benefits of adding significant uncorrelated factors to the basic model.

Prediction accuracy gained by adding significant factors identified to basic model in predicting fulminant myocarditis risk. Decision curve analysis on the net benefits of adding significant uncorrelated factors to the basic model.

Prediction nomogram model

A prediction nomogram model was established for fulminant myocarditis on the basis of identified significant predictors, including MAP, creatinine, BUN, AST, TNI, and VWMA (Fig. 2). The predictive accuracy was good, as reflected by both C-index of over 90% (P < .001) and calibration curve (Supplementary Figure 2).
Figure 2

The prediction nomogram model for fulminant myocarditis. AST = aspartate aminotransferase, BUN = blood urea nitrogen, MAP = mean arterial pressure, TNI = Troponin I, VWMA = ventricular wall motion abnormality.

The prediction nomogram model for fulminant myocarditis. AST = aspartate aminotransferase, BUN = blood urea nitrogen, MAP = mean arterial pressure, TNI = Troponin I, VWMA = ventricular wall motion abnormality.

Changes of predictive echocardiographic performance during follow-ups

As illustrated in Fig. 3, in patients with fulminant myocarditis, LVPWT was significantly decreased at 3rd month after discharge from hospital, whereas SV and LVEF were significantly increased.
Figure 3

Changes of predictive echocardiographic measurements during follow-ups. M = fulminant myocarditis, IVPWT = left ventricular posterior wall thickness, LVEF = left ventricular ejection fraction, NFM = non-fulminant myocarditis, SV = stroke volume.

Changes of predictive echocardiographic measurements during follow-ups. M = fulminant myocarditis, IVPWT = left ventricular posterior wall thickness, LVEF = left ventricular ejection fraction, NFM = non-fulminant myocarditis, SV = stroke volume.

Discussion

In this retrospective, cross-sectional study, we aimed to identify potential predictors associated with the risk of fulminant myocarditis in a Chinese population. The key finding of this study is that 6 unrelated clinical factors were identified to be significantly associated with fulminant myocarditis, including MAP, creatinine, BUN, D-dimer, AST, TNI, and VWMA, and importantly their prediction capability was more obvious in a nomogram model. To the best of our knowledge, this is the first study that has established and assessed a prediction nomogram model for fulminant myocarditis in current literature. Some studies have attempted to unravel the risk profiling of fulminant myocarditis by focusing on individual factors, whereas disregarding the establishment of risk scores or prediction models.[ Considering the fact that fulminant myocarditis is a complex fatal disease, the role of any single factors in the pathogenesis of fulminant myocarditis is likely to be small when assessed individually, but may be more pronounced in the presence of other risk factors. To shed some light on this issue, we employed the logistic regression analyses before and after adjusting for confounding factors, as well as the Spearman correlation analyses to identify potential unrelated factors that are independently and significantly associated with the risk of fulminant myocarditis, and finally 6 such factors were teased out. To appraise prediction performance, we conducted both Hosmer–Lemeshow and likelihood ratio tests, as well as AIC, BIC, net reclassification improvement (NRI), IDI, and AUROC statistics and visual inspection of decision curve analysis curves. These multi-angle analyses revealed that the addition of 6 identified factors can significantly improve the prediction capability of the basic model. To enhance clinical practicability, we here established a nomogram model by regressing these 6 factors, with a decent prediction accuracy. For practical reasons, we agree that external validation of our findings is of added interest. Consistent with the results of previous studies,[ our findings indicated that both cardiac and renal dysfunction made a critical difference in the progress of fulminant myocarditis. It is widely recognized that cardiac and renal diseases interplay bilaterally and interdependently due to shared pathways,[ which may be explained by over-activation of the neurohormonal systems (such as renin-angiotensin-aldosterone system) and elevated venous pressure.[ Consequently, monitoring renal function and providing timely intervention are of vital importance at the early onset of fulminant myocarditis. Additionally, we found that increased D-dimer level was associated with a high risk of fulminant myocarditis. D-dimer is regarded as a valuable biomarker of coagulation and fibrinolysis,[ which can be induced by inflammation and further interact with each other.[ Moreover, there is a large population study suggesting that D-dimer can independently lead to functional decline and mortality.[ Both dependent and independent impacts of D-dimer play essential roles in the development of fulminant myocarditis, and so it is necessary to give more concerns to patients with increased D-dimer level, especially those with sharp D-dimer increment.[ In terms of echocardiographic characteristics, our findings highlight the important roles of IVPWT, SV, and LVEF in predicting fulminant myocarditis. Thicker IVPWT reflects structural changes in heart at early onset, whereas decreased SV and LVEF reflect functional changes. Those changes are mainly caused by inflammatory response and edema,[ and can remarkably recover within a short period in our study. However, there is a paucity of data regarding the adverse outcomes of fulminant myocarditis.[ This discrepancy may be determined by histologic subtype, with giant cell myocarditis portending the worst prognosis.[ Yet, detection of histologic changes, depending on results of endomyocardial biopsy, is restricted due to hemodynamic dysfunction of fulminant myocarditis.

Limitations

Some limitations should be acknowledged when interpreting our findings. Firstly, this study is cross-sectional in design, which precludes further comments on causality, and more prospective investigations with longer follow-up intervals are warranted. Secondly, given the fact that the prevalence of fulminant myocarditis is extremely low, the sample size of our study was relatively small. Further large-scale studies are needed to confirm or refute our conclusions. Thirdly, all study subjects were enrolled from a single hospital in Fuzhou, China, which restricts the generalizability of our findings to other groups.

Conclusions

Taken together, we have identified 6 clinical factors in significant association with fulminant myocarditis, and their prediction capability was more obvious in a nomogram model. For practical reasons, we hope that this study will not be just an end point of explorations instead of a start to establish underpinning data to further identify and characterize risk profiling of fulminant myocarditis, as well as the potential biological mechanisms.

Acknowledgments

The authors gratefully thank the assistance and cooperation of the faculty and staff of the Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, as well as the subjects under the current study for their enthusiastic participation.

Author contributions

Conceptualization: Feizhen Chen. Data curation: Guifen Xu, Feizhen Chen, Wei Zhuang, Fuling Yu. Formal analysis: Guifen Xu, Wenxiang Zhao, Yong Zheng. Methodology: Guifen Xu, Wenxiang Zhao, Yong Zheng, Wei Zhuang. Project administration: Feizhen Chen, Fuling Yu. Software: Guifen Xu, Wenxiang Zhao, Yong Zheng, Wei Zhuang. Supervision: Fuling Yu. Validation: Fuling Yu. Writing – original draft: Guifen Xu. Writing – review & editing: Fuling Yu.
  28 in total

Review 1.  Inflammation and coagulation.

Authors:  Marcel Levi; Tom van der Poll
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

Review 2.  Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort.

Authors:  Santiago Montero; Nadia Aissaoui; Jean-Marc Tadié; Philippe Bizouarn; Vincent Scherrer; Romain Persichini; Clément Delmas; Florence Rolle; Emmanuel Besnier; Alexandre Le Guyader; Alain Combes; Matthieu Schmidt
Journal:  Int J Cardiol       Date:  2018-02-15       Impact factor: 4.164

3.  Temporal echocardiography findings in patients with fulminant myocarditis: beyond ejection fraction decline.

Authors:  Houjuan Zuo; Rui Li; Fei Ma; Jiangang Jiang; Kun Miao; Haojie Li; Eike Nagel; Marijana Tadic; Hong Wang; Dao Wen Wang
Journal:  Front Med       Date:  2019-12-19       Impact factor: 4.592

4.  Thioredoxin, adiponectin and clinical course of acute fulminant myocarditis.

Authors:  Jin-Oh Choi; Soo-Hyeon Yun; Kiick Sung; Young Tak Lee; Joong-Il Park; Eun-Seon Ju; Sang-Chol Lee; Seung Woo Park; Duk-Kyung Kim; Jae K Oh; Eun-Seok Jeon
Journal:  Heart       Date:  2011-05-10       Impact factor: 5.994

5.  Echocardiographic findings in fulminant and acute myocarditis.

Authors:  G M Felker; J P Boehmer; R H Hruban; G M Hutchins; E K Kasper; K L Baughman; J M Hare
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

6.  Risk factors for patients developing a fulminant course with acute myocarditis.

Authors:  Shigeru Kato; Shin-Ichiro Morimoto; Shinya Hiramitsu; Akihisa Uemura; Masatsugu Ohtsuki; Yasuchika Kato; Kenji Miyagishima; Yukihiko Yoshida; Shuji Hashimoto; Hitoshi Hishida
Journal:  Circ J       Date:  2004-08       Impact factor: 2.993

Review 7.  Cardiorenal syndrome: review of our current understanding.

Authors:  Savvas Hadjiphilippou; Sui Phin Kon
Journal:  J R Soc Med       Date:  2015-11-25       Impact factor: 5.344

8.  Associations between fibrin D-dimer, markers of inflammation, incident self-reported mobility limitation, and all-cause mortality in older men.

Authors:  S Goya Wannamethee; Peter H Whincup; Lucy Lennon; Olia Papacosta; Gordon D Lowe
Journal:  J Am Geriatr Soc       Date:  2014-12       Impact factor: 5.562

Review 9.  Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis.

Authors:  Daowen Wang; Sheng Li; Jiangang Jiang; Jiangtao Yan; Chunxia Zhao; Yan Wang; Yexin Ma; Hesong Zeng; Xiaomei Guo; Hong Wang; Jiarong Tang; Houjuan Zuo; Li Lin; Guanglin Cui
Journal:  Sci China Life Sci       Date:  2018-12-03       Impact factor: 6.038

10.  Early characteristics of fulminant myocarditis vs non-fulminant myocarditis: A meta-analysis.

Authors:  Zicheng Wang; Yanwei Wang; Haiyan Lin; Shengjie Wang; Xianlei Cai; Da Gao
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.